TWI747929B - 一種人胰島素或其類似物的醯化衍生物 - Google Patents

一種人胰島素或其類似物的醯化衍生物 Download PDF

Info

Publication number
TWI747929B
TWI747929B TW106125882A TW106125882A TWI747929B TW I747929 B TWI747929 B TW I747929B TW 106125882 A TW106125882 A TW 106125882A TW 106125882 A TW106125882 A TW 106125882A TW I747929 B TWI747929 B TW I747929B
Authority
TW
Taiwan
Prior art keywords
patent application
scope
human insulin
item
zinc complex
Prior art date
Application number
TW106125882A
Other languages
English (en)
Chinese (zh)
Other versions
TW201805300A (zh
Inventor
劉德玉
王宏偉
趙亮
王菲菲
曾翔
王濤
王亞里
戴雨璐
Original Assignee
大陸商江蘇恆瑞醫藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商江蘇恆瑞醫藥股份有限公司 filed Critical 大陸商江蘇恆瑞醫藥股份有限公司
Publication of TW201805300A publication Critical patent/TW201805300A/zh
Application granted granted Critical
Publication of TWI747929B publication Critical patent/TWI747929B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
TW106125882A 2016-08-02 2017-08-01 一種人胰島素或其類似物的醯化衍生物 TWI747929B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN201610625257.5 2016-08-02
CN201610625257 2016-08-02
??201610625257.5 2016-08-02
CN201610779132 2016-08-31
??201610779132.8 2016-08-31
CN201610779132.8 2016-08-31

Publications (2)

Publication Number Publication Date
TW201805300A TW201805300A (zh) 2018-02-16
TWI747929B true TWI747929B (zh) 2021-12-01

Family

ID=61074099

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106125882A TWI747929B (zh) 2016-08-02 2017-08-01 一種人胰島素或其類似物的醯化衍生物

Country Status (6)

Country Link
US (1) US10815287B2 (enExample)
EP (1) EP3495384A4 (enExample)
JP (2) JP7432361B2 (enExample)
CN (2) CN114478747B (enExample)
TW (1) TWI747929B (enExample)
WO (1) WO2018024186A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111315766B (zh) * 2018-02-01 2023-05-12 江苏恒瑞医药股份有限公司 含人胰岛素类似物的酰化衍生物的药物组合物及其制备方法
AU2019218315A1 (en) 2018-02-09 2020-07-09 Jiangsu Hengrui Medicine Co., Ltd. Codon optimized precursor gene and signal peptide gene of human insulin analogue
WO2019223752A1 (zh) 2018-05-24 2019-11-28 江苏恒瑞医药股份有限公司 一种重组人胰岛素或其类似物的前体的制备方法
WO2020120463A1 (en) 2018-12-11 2020-06-18 Sanofi Insulin conjugates
CN118420743A (zh) * 2019-12-30 2024-08-02 甘李药业股份有限公司 胰岛素衍生物
CN116583531A (zh) * 2020-11-27 2023-08-11 江苏恒瑞医药股份有限公司 一种制备胰岛素或其类似物的酰化衍生物的方法
CN112939771A (zh) * 2021-01-28 2021-06-11 宁夏蓝博思化学技术有限公司 长链烷基二酸单叔丁酯的制备方法
US20240374692A1 (en) 2021-05-24 2024-11-14 Sunshine Lake Pharma Co., Ltd. A novel acylated insulin analog
US20250262282A1 (en) 2021-06-25 2025-08-21 Gan & Lee Pharmaceuticals Co., Ltd. Acylated Insulin-Containing Pharmaceutical Composition
US20250340610A1 (en) 2022-01-28 2025-11-06 Gan & Lee Pharmaceuticals Co., Ltd. Acylated insulin
CN117756914B (zh) * 2023-12-15 2024-09-03 瀚晖制药有限公司 依柯胰岛素的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012347A2 (en) * 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
TW201323439A (zh) * 2011-12-15 2013-06-16 Shanghai Hengrui Pharm Co Ltd 人胰島素類似物及其醯化衍生物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
SK282495B6 (sk) * 1993-09-17 2002-02-05 Novo Nordisk A/S Acylovaný inzulínový derivát a farmaceutický prostriedok, ktorý ho obsahuje
CN1163574A (zh) * 1994-11-17 1997-10-29 伊莱利利公司 酰化的胰岛素类似物
US6310038B1 (en) * 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
WO2003075950A1 (en) * 2002-03-13 2003-09-18 Novo Nordisk A/S Minimising body weight gain in insulin treatment
PL2275439T3 (pl) 2003-08-05 2014-09-30 Novo Nordisk As Nowe pochodne insuliny
DK1969004T3 (da) * 2005-12-28 2011-11-28 Novo Nordisk As Insulinsammensætninger og metode til at lave en sammensætning
EP2178910B1 (en) * 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
KR20110004366A (ko) * 2008-03-18 2011-01-13 노보 노르디스크 에이/에스 프로테아제 안정화되고, 아실화된 인슐린 유사체
US8935928B2 (en) * 2011-10-10 2015-01-20 Lockheed Martin Corporation Integrated air-cycle refrigeration and power generation system
CN106496322A (zh) * 2015-09-07 2017-03-15 江苏恒瑞医药股份有限公司 人胰岛素或其类似物的酰化衍生物的制备方法
WO2017136834A1 (en) * 2016-02-05 2017-08-10 Memorial Sloan-Ketering Cancer Center Methods of differentiating stem cell-derived ectodermal lineage precursors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012347A2 (en) * 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
TW201323439A (zh) * 2011-12-15 2013-06-16 Shanghai Hengrui Pharm Co Ltd 人胰島素類似物及其醯化衍生物

Also Published As

Publication number Publication date
TW201805300A (zh) 2018-02-16
EP3495384A1 (en) 2019-06-12
CN114478747A (zh) 2022-05-13
WO2018024186A1 (zh) 2018-02-08
JP7432361B2 (ja) 2024-02-16
JP2022095872A (ja) 2022-06-28
CN108463468A (zh) 2018-08-28
JP2019526537A (ja) 2019-09-19
EP3495384A4 (en) 2020-02-26
US10815287B2 (en) 2020-10-27
CN114478747B (zh) 2024-06-14
CN108463468B (zh) 2022-03-04
US20190169257A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
TWI747929B (zh) 一種人胰島素或其類似物的醯化衍生物
JP6084215B2 (ja) ポリエチレングリコールまたはその誘導体でｐｅｇ化されたエキセンジン−４類似体、その調製法、および活性成分としてこれを含有する、糖尿病を予防または処置するための薬学的組成物
ES2611040T3 (es) Derivados de insulina
US9260503B2 (en) Multi-substituted insulins
RU2531590C2 (ru) Аналоги глюкагоноподобного пептида-1 и их применение
CN114796462A (zh) 一种长效glp-1衍生物的药物制剂
US10400021B2 (en) Acylated insulin compound
CA3084688A1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
CN115385843A (zh) 一种新型的酰化胰岛素类似物
CN115947822A (zh) 一种长效酰化胰岛素衍生物及其药物组合物和应用
TWI740099B (zh) 含人胰島素類似物的醯化衍生物的藥物組合物及其製備方法
CN106554404A (zh) 一种艾塞那肽修饰物及其用途
CN114450300B (zh) 新颖的化合物
EP3373953A1 (fr) Composition a action rapide d'insuline comprenant un citrate substitue
HK1255297A1 (en) Acylated derivative of human insulin or analogue thereof
HK1255297B (en) Acylated derivative of human insulin or analogue thereof
JP2013527160A (ja) グルカゴン様ペプチド−１類似体およびその使用
CN101437849B (zh) 胰岛素衍生物
HK40032575A (en) Pharmaceutical composition comprising acylated derivative of human insulin analog and preparation method thereof
HK40032575B (en) Pharmaceutical composition comprising acylated derivative of human insulin analog and preparation method thereof
CN120647550A (zh) 一种用于修饰GLP-1/GIP/glucagon受体激动剂的脂肪酸链及其应用
HK1162526A1 (en) Glp-1 derivatives and uses thereof
HK1162037B (en) Glucagon-like peptide-1 analogue and use thereof